| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H40O2 |
| Molecular Weight | 360.5732 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CCCC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O
InChI
InChIKey=RPKLZQLYODPWTM-LVVAJZGHSA-N
InChI=1S/C24H40O2/c1-16(7-12-22(25)26)19-10-11-20-18-9-8-17-6-4-5-14-23(17,2)21(18)13-15-24(19,20)3/h16-21H,4-15H2,1-3H3,(H,25,26)/t16-,17+,18+,19-,20+,21+,23+,24-/m1/s1
Cholanic acid is the archetypal C24 bile acid skeleton from which all other C24 bile acids can be derived. Of the two common isomers: 5alpha and 5Beta, the last isomer is the most biologically relevant. 5-Beta Cholanic Acid has been studied as a modulator of the gamma-secretase complex as it pertains to Alzheimer's disease; it has also been identified as an inhibitor of the Ephrin type-A receptor 2 that is involved in cancer cell signaling and angiogenesis.
Approval Year
PubMed
Sample Use Guides
C14 labeled cholanic acid sodium salt was administered intraperitoneally at a dose of 0.7 mg (1.54 x 10^6 d.p.m. per mg) to rats with bile fistulas, and rats with ligated bile ducts. The excreta was monitored for C14 labeled metabolites.
Route of Administration:
Intraperitoneal
SUBSTANCE RECORD
